Stifel Financial’s Kyverna Therapeutics KYTX Stock Holding History

Stifel Financial’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$951K	Sell	139,922 -43	-0%	-$339	﹤0.01%	2583
2026 Q2	$1.25M	Buy	139,965 +9,441	+7%	+$83.8K	﹤0.01%	2410
2026 Q1	$1.13M	Buy	130,524 +4,734	+4%	+$39.4K	﹤0.01%	2384
2025 Q4	$1.18M	Buy	125,790 +86,969	+224%	+$646K	﹤0.01%	2324
2025 Q3	$233K	Sell	38,821 -144	-0.4%	-$576	﹤0.01%	3263
2025 Q2	$120K	Sell	38,965 -198	-0.5%	-$490	﹤0.01%	3346
2025 Q1	$75.6K	Sell	39,163 -179	-0.5%	-$529	﹤0.01%	3317
2024 Q4	$147K	Buy	+39,342	New	+$188K	﹤0.01%	3208

Other funds holding KYTX

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Stifel Financial's KYTX Position: Q3 2026 in Review

Stifel Financial reduced its Kyverna Therapeutics (KYTX) stake by 0.03% in Q3 2026, selling an estimated $339 and leaving 139,922 shares worth $951K. The position accounts for ﹤0.01% of the portfolio, ranked #2583.

Stifel Financial first reported a position in KYTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.25M in Q2 2026. 64 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

Stifel Financial held 139,922 shares of Kyverna Therapeutics worth $951K as of Q3 2026.
Stifel Financial sold 43 Kyverna Therapeutics shares in Q3 2026, an estimated $339.
Kyverna Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #2583 holding.
Stifel Financial first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 8 quarters since.
Stifel Financial's Kyverna Therapeutics position peaked at $1.25M in Q2 2026.
64 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.